Scandinavian Chemotech Ab Stock Current Asset
| CMOTEC-B | SEK 1.74 0.04 2.35% |
Scandinavian ChemoTech AB fundamentals help investors to digest information that contributes to Scandinavian ChemoTech's financial success or failures. It also enables traders to predict the movement of Scandinavian Stock. The fundamental analysis module provides a way to measure Scandinavian ChemoTech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scandinavian ChemoTech stock.
Scandinavian |
Scandinavian ChemoTech AB Company Current Asset Analysis
Scandinavian ChemoTech's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Scandinavian ChemoTech AB has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Sweden stocks is 100.0% higher than that of the company.
Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
Scandinavian Fundamentals
| Return On Equity | -1.17 | |||
| Return On Asset | -0.51 | |||
| Operating Margin | (48.69) % | |||
| Current Valuation | 68.38 M | |||
| Shares Outstanding | 10.64 M | |||
| Shares Owned By Insiders | 26.03 % | |||
| Shares Owned By Institutions | 3.32 % | |||
| Price To Book | 8.87 X | |||
| Price To Sales | 159.69 X | |||
| Revenue | 49 K | |||
| Gross Profit | 2.86 M | |||
| EBITDA | (20.02 M) | |||
| Net Income | (17.74 M) | |||
| Cash And Equivalents | 5.62 M | |||
| Cash Per Share | 1.65 X | |||
| Total Debt | 53 K | |||
| Debt To Equity | 2.10 % | |||
| Current Ratio | 7.09 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (19.18 M) | |||
| Earnings Per Share | (2.19) X | |||
| Beta | 1.56 | |||
| Market Capitalization | 113.35 M | |||
| Total Asset | 25.81 M | |||
| Net Asset | 25.81 M |
About Scandinavian ChemoTech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scandinavian ChemoTech AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandinavian ChemoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandinavian ChemoTech AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Scandinavian Stock
Scandinavian ChemoTech financial ratios help investors to determine whether Scandinavian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Scandinavian with respect to the benefits of owning Scandinavian ChemoTech security.